Evidence map›Paper›PMID 40650142›Full record

ArticleInternational journal of molecular sciences2025

CRISPRa-Mediated Increase of OPA1 Expression in Dominant Optic Atrophy.

Giada Becchi, Michael Whitehead, Joshua P Harvey, Paul E Sladen, Mohammed Dushti, J Paul Chapple, Patrick Yu-Wai-Man, Michael E Cheetham

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Giada BecchiUCL Institute of Ophthalmology, Faculty of Brain Sciences, London EC1V 9EL, UK.ORCID 0009-0005-1918-3825
Michael WhiteheadUCL Institute of Ophthalmology, Faculty of Brain Sciences, London EC1V 9EL, UK.
Joshua P HarveyUCL Institute of Ophthalmology, Faculty of Brain Sciences, London EC1V 9EL, UK.
Paul E SladenUCL Institute of Ophthalmology, Faculty of Brain Sciences, London EC1V 9EL, UK.
Mohammed DushtiWilliam Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.
J Paul ChappleWilliam Harvey Research Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.ORCID 0000-0003-1876-1505
Patrick Yu-Wai-ManJohn van Geest Centre for Brain Repair, University of Cambridge, Cambridge CB2 0PY, UK.ORCID 0000-0001-7847-9320
Michael E CheethamUCL Institute of Ophthalmology, Faculty of Brain Sciences, London EC1V 9EL, UK.ORCID 0000-0001-6429-654X

Funding

Fight for Sight 5167/5168
6 · The paper itself

Abstract

Dominant Optic Atrophy (DOA) is the most common inherited optic neuropathy and presents as gradual visual loss caused by the loss of retinal ganglion cells (RGCs). Over 60% of DOA cases are caused by pathogenic variants in the

Indexed as

CRISPR-Cas SystemsGTP PhosphohydrolasesOptic Atrophy, Autosomal DominantGene EditingGene Expression RegulationHEK293 CellsHumansMitochondriaRetinal Ganglion CellsRNA, Guide, CRISPR-Cas SystemsGTP PhosphohydrolasesOPA1 protein, humanRNA, Guide, CRISPR-Cas Systemsalternative splicingCRISPRCRISPR activationgene editinggene expressionmitochondriamitochondrial fusionOPA1optic atrophyretinal ganglion cell

Identifiers

PMID40650142
PMCPMC12249591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.